Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1996 1
1998 2
1999 2
2000 6
2001 2
2002 4
2003 8
2004 3
2005 3
2006 2
2007 1
2008 1
2009 2
2010 3
2011 2
2012 3
2013 4
2014 3
2015 3
2016 4
2017 2
2018 3
2019 2
2020 5
2021 7
2022 1
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Results by year
Filters applied: . Clear all
Page 1
Paternal use of ribavirin-interferon alpha 2B combination therapy before conception.
Taguchi N, Ito S. Taguchi N, et al. Can Fam Physician. 2005 Dec;51(12):1623-5. Can Fam Physician. 2005. PMID: 16805078 Free PMC article. Review.
QUESTION: One of my male patients is receiving ribavirin-interferon alpha 2B (Pegetron) combination therapy for chronic hepatitis C. ...ANSWER: To the best of our knowledge, paternal exposure to ribavirin-interferon alpha 2B has no adverse effects on r …
QUESTION: One of my male patients is receiving ribavirin-interferon alpha 2B (Pegetron) combination therapy for chronic hepati …
Inosine triphosphate pyrophosphatase polymorphisms are predictors of anemia in Chinese patients with chronic hepatitis C during therapy with ribavirin and interferon.
Chi X, Wang M, Pan Y, Jiang J, Jiang T, Yan H, Wu R, Wang X, Gao X, Niu J. Chi X, et al. J Gastroenterol Hepatol. 2020 Jan;35(1):97-103. doi: 10.1111/jgh.14812. Epub 2019 Aug 23. J Gastroenterol Hepatol. 2020. PMID: 31359493
BACKGROUND AND AIM: Polymorphisms of inosine triphosphate pyrophosphatase (rs1127354 and rs6051702) and interferon lambda 4 (IFLN4) (rs12979860) are indicators of anemia and/or sustained virological response (SVR) in patients with chronic hepatitis C on ribavirin/ …
BACKGROUND AND AIM: Polymorphisms of inosine triphosphate pyrophosphatase (rs1127354 and rs6051702) and interferon lambda 4 (IFLN4) ( …
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Wong JB, Davis GL, Pauker SG. Wong JB, et al. Am J Med. 2000 Apr 1;108(5):366-73. doi: 10.1016/s0002-9343(00)00303-x. Am J Med. 2000. PMID: 10759092 Clinical Trial.
PURPOSE: Many patients with chronic hepatitis C who are treated with interferon suffer a relapse after an initial response. About half of these patients have a sustained virological response to retreatment with the combination of ribavirin and interferon alfa …
PURPOSE: Many patients with chronic hepatitis C who are treated with interferon suffer a relapse after an initial response. About hal …
Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
Riedel DJ, Taylor S, Simango R, Kiromera A, Sebeza J, Baribwira C, Musabeyezu E. Riedel DJ, et al. Trans R Soc Trop Med Hyg. 2016 Aug;110(8):495-7. doi: 10.1093/trstmh/trw055. Epub 2016 Sep 12. Trans R Soc Trop Med Hyg. 2016. PMID: 27618922
METHODS: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014. ...HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and …
METHODS: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, …
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, Kraehenbuhl S, Locher S, Egger HP, Clavien PA, Hadengue A, Mentha G, Morel P, Negro F. Giostra E, et al. Transpl Int. 2004 May;17(4):169-76. doi: 10.1007/s00147-004-0695-6. Epub 2004 Apr 2. Transpl Int. 2004. PMID: 15060764 Free article. Clinical Trial.
In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg body weight q.d.) for 12 weeks, followed by ribavirin at the same dose q.d. plus interferon-alpha (IFN-alpha) [3 million units …
In an uncontrolled trial, 31 patients with histologically confirmed hepatitis C after LT received, sequentially, ribavirin (10 mg/kg …
Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses.
Crance JM, Scaramozzino N, Jouan A, Garin D. Crance JM, et al. Antiviral Res. 2003 Mar;58(1):73-9. doi: 10.1016/s0166-3542(02)00185-7. Antiviral Res. 2003. PMID: 12719009
Ribavirin, interferon-alpha (IFN-alpha), 6-azauridine and glycyrrhizin were tested in vitro for their antiviral activities against 11 pathogenic flaviviruses belonging to principal antigenic complexes or individual serogroups of medical importance: dengue, Japanese …
Ribavirin, interferon-alpha (IFN-alpha), 6-azauridine and glycyrrhizin were tested in vitro for their antiviral activities aga …
Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy.
Shan W, Hong D, Zhu J, Zhao Q. Shan W, et al. Comput Math Methods Med. 2020 Sep 24;2020:1391583. doi: 10.1155/2020/1391583. eCollection 2020. Comput Math Methods Med. 2020. PMID: 33029193 Free PMC article.
PURPOSE: We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in th …
PURPOSE: We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US …
Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E. Hofmann WP, et al. Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821. Antivir Ther. 2011. PMID: 21817191
Triple combinations with ribavirin, interferon-alpha and protease inhibitors showed the most profound HCV RNA decay. CONCLUSIONS: The beneficial in vitro antiviral effect of ribavirin with interferon-alpha and novel HCV protease inhibitors demonstrates …
Triple combinations with ribavirin, interferon-alpha and protease inhibitors showed the most profound HCV RNA decay. CONCLUSIO …
Improved response to ribavirin interferon combination compared with interferon alone in patients with type 4 chronic hepatitis C without cirrhosis.
Koshy A, Marcellin P, Martinot M, Madda JP. Koshy A, et al. Liver. 2000 Jul;20(4):335-9. doi: 10.1034/j.1600-0676.2000.020004335.x. Liver. 2000. PMID: 10959813 Clinical Trial.
AIM: This study was undertaken in order to determine the response of genotype 4 chronic hepatitis C to interferon and ribavirin combination compared to interferon alone in patients without cirrhosis. ...Only 4/52 (8%) patients showed sustained virologic respo …
AIM: This study was undertaken in order to determine the response of genotype 4 chronic hepatitis C to interferon and ribavirin …
71 results